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Objective To compare the impact of 1000 lg of self-administered
vaginal misoprostol versus self-administered vaginal placebo on
preoperative cervical ripening after 2 weeks of pretreatment with
estradiol vaginal tablets in postmenopausal women prior to
day-care operative hysteroscopy.
Design Randomised, double-blind, placebo-controlled sequential
trial.
Setting Norwegian university teaching hospital.
Population Sixty-seven postmenopausal women referred for day-
care operative hysteroscopy.
Methods The women were randomised to receive either 1000 lg
of self-administered vaginal misoprostol or self-administered
vaginal placebo on the evening before day-care operative
hysteroscopy. All women had administered a 25-lg vaginal
estradiol tablet daily for 14 days prior to the operation.
Main outcome measures Primary outcome: preoperative cervical
dilatation at hysteroscopy. Secondary outcomes: difference in
dilatation at recruitment and before hysteroscopy, number of
women who achieved a preoperative cervical dilatation of 5 mm
or more, acceptability, complications and adverse effects.
Results The mean cervical dilatation was 5.7 mm (SD, 1.6 mm) in
the misoprostol group and 4.7 mm (SD, 1.5 mm) in the placebo
group, the mean difference in cervical dilatation being 1.0 mm
(95% CI, 0.2–1.7 mm). Self-administered vaginal misoprostol of
1000 lg at home on the evening before day-care hysteroscopy is
safe and highly acceptable, although a small proportion of women
experienced lower abdominal pain.
Conclusions One thousand micrograms of self-administered
vaginal misoprostol, 12 hours prior to day-care hysteroscopy, after
14 days of pretreatment with vaginal estradiol, has a signiﬁcant
cervical ripening effect compared with placebo in postmenopausal
women.
Keywords Cervical ripening, estradiol, hysteroscopy, misoprostol,
postmenopausal, sequential trial.
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Introduction
Ripening or softening of the uterine cervical tissue is a pro-
cess involving various inﬂammatory reactions,
1,2 although
the mechanisms are poorly understood. Ripening of the
cervix in early pregnancy is recommended before surgical
abortion to facilitate cervical dilatation,
3 later in pregnancy
to induce labour,
4 and in non-pregnant women if intra-
uterine surgery is indicated.
5,6 Several methods are effective
for ripening the cervix: mechanically with osmotic dilators
7
or balloon catheters,
8 and biochemically with prostaglan-
dins,
9 antiprogestins
10 or nitric oxide donors,
11 although
prostaglandins are the most commonly used agent for
cervical ripening and labour induction.
Cervical ripening and labour induction occur by the acti-
vation of the prostaglandin E2 receptor by prostaglandins.
12
The prostaglandin E1 analogue misoprostol, originally
developed as an antigastric ulcer drug,
13 has superseded
licensed prostaglandins used for cervical ripening and
labour induction. It is mostly used off-label, as the patent
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licences for gynaecological or obstetrical use. There is
abundant literature supporting its safety and effectiveness
for multiple reproductive health indications.
14
Many patients require cervical dilatation prior to opera-
tive hysteroscopy, depending on the size of the instrument
used for the operation. An operative hysteroscope/resecto-
scope used to treat endometrial pathology typically has a
diameter of 10 mm. In women with a ﬁrmly closed and
rigid cervix, dilatation can lead to considerable traumatisa-
tion of the tissue. Furthermore, complicated cervical dilata-
tion is attended by the risk of lacerations caused by the
tenaculum, the creation of false passages and an increased
risk of uterine perforation. Maximum forces of more than
100 N have been measured for dilatation up to Hegar 6.
15
Nulliparous and postmenopausal women are particularly at
risk of complications.
16–20
Prostaglandins have been used for cervical ripening prior
to hysteroscopy since 1985.
21 The analogues licensed for
gynaecological use are both expensive and impractical to
use for this purpose (e.g. intracervical application of sul-
prostone gel). As misoprostol is inexpensive, easy to obtain
and to use, and has a long shelf-life, it has been employed
as a cervical ripening agent before operative hysteroscopy
in order to reduce the complications occurring during the
dilatation procedure.
22 In a previous study, we found that
the cervix of over 40% of postmenopausal women was
judged to be difﬁcult to dilate and that misoprostol
appeared to be effective for cervical ripening in premeno-
pausal, but not postmenopausal, women.
23 A relative lack
of estrogen in postmenopausal women could possibly be
the main reason why misoprostol appears to have no sig-
niﬁcant cervical ripening effect.
Hypothesis
The null hypothesis is that there is no clinically signiﬁcant
difference in preoperative cervical dilatation just before
hysteroscopy (<1 mm) between postmenopausal women
who receive vaginal misoprostol and postmenopausal
women who receive vaginal placebo. Both groups were pre-
treated with vaginal estradiol for 14 days.
Methods
Patients
We refer to the previously published trial protocol for
comprehensive methodological details.
24 Those eligible for
the study were all postmenopausal women (deﬁned as at
least 1 year after the last menstrual period/menstruation)
referred consecutively for day-care operative hysteroscopy,
and who had provided informed written consent. Women
were excluded if they did not want to participate, if they
were medically unﬁt for hysteroscopy or for participation
in any clinical trial, or if they did not have a medical indi-
cation for hysteroscopy. Other exclusion criteria were pre-
vious or current breast or gynaecological cancer, a medical
contraindication for locally applied estradiol or misopros-
tol, the current use of hormone therapy or unable to com-
municate in Norwegian.
Procedures
Before a cervical smear and endometrial biopsy were taken
as part of the routine outpatient examination, cervical dila-
tation was measured by passing Hegar dilators through the
cervix in ascending order, starting with a Hegar dilator of
size 2 mm. Women participating in the study started daily
treatment with 25-lg estradiol vaginal tablets for 2 weeks
before operative hysteroscopy. Participants were randomly
assigned at a ratio of 1:1 to 1000 lg of vaginal misoprostol
or placebo, according to a randomised list of three per-
muted blocks on a double-blind basis at the outpatient
consultation. The hospital pharmacist manufactured the
study drug and placebo capsules, which were delivered in
numbered containers. The study participants were
instructed to insert the misoprostol/placebo capsules vagi-
nally, as deep as possible, after voiding urine at approxi-
mately 21.00 hours on the evening before the operation.
Both patient and examiner were blind to randomisation.
The primary efﬁcacy outcome was the degree of cervical
dilatation, immediately before hysteroscopy, assessed by
passing Hegar dilators through the cervix in ascending
order, starting with a size of 2 mm. Six experienced senior
gynaecologists performed the operative hysteroscopies dur-
ing the study period. Prior to the operation on the ﬁrst
woman, the project leader individually instructed the oper-
ators in how to assess preoperative cervical dilatation in
order to obtain valid and reliable measurements. The size
of the largest dilator passed into the internal cervical os
without subjective resistance felt by the operator was
recorded as the preoperative degree of dilatation. Secondary
outcomes included the number of dilatations judged as
‘easy’ or ‘difﬁcult’ by the operator, the time used to dilate
the cervix, and the difference between the baseline cervical
dilatation at recruitment and preoperative dilatation at
hysteroscopy. Further data recorded were the symptoms
and adverse effects experienced between the insertion of
capsules and the operation, as well as the frequency of
adverse events and complications during hysteroscopy and
during the 14-day follow-up period, the acceptability of the
treatment by the women and the histological result.
The trial was conducted in accordance with the Declara-
tion of Helsinki and national as well as local regulations. The
Regional Committee for Medical Research Ethics (Regional
komite ´ for medisinsk forskningsetikk, Nord-Norge, REK
Nord) in Northern Norway (Ref no. 200704112-5/MRO/
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Ofﬁcer (Personvernansvarlig) approved the protocol. Authori-
sation from the Norwegian Medicines Agency (Statens Lege-
middelverk, SLV) was granted (Ref. no. 07/12515-8) for the
study. The trial is registered with ClinicalTrials.gov, number
NCT00572819, the European Clinical Trials Database,
number 2007-004083-52, and the study protocol has been
published in BJOG.
24 Written informed consent was
obtained from all patients before randomisation.
Statistical analysis
A two-sample sequential Wilcoxon test, developed by
Skovlund and Walløe,
25–27 was used in order to reduce the
number of study participants needed to reach a conclusion
on the primary outcome. This method has been used previ-
ously in relatively few clinical trials, but has been proven to
be easy to use and robust. It is expected to reduce the
number of study participants needed to reach a conclusion,
compared with the number required in a corresponding
ﬁxed sample trial.
28,29 The analysis is tailored to reach a
conclusion on the primary outcome as soon as the differ-
ence is statistically signiﬁcant, so that as few study partici-
pants as possible are enrolled. The boundaries needed for
the statistical model were calculated on the basis of the
preoperative variability (SD) in cervical dilatation in post-
menopausal women from our previous trial, the mean
cervical dilatation being 4.1 mm and SD 2.3 mm.
23 The
design of the main trial is based on a signiﬁcance level of
5% and a power of 95% against a 1-mm difference in the
cervical dilatation caused by misoprostol and placebo. As it
seemed clinically unlikely that the use of misoprostol would
cause a constriction of the cervix, a one-sided test was cho-
sen. The trial was halted when the boundary for signiﬁ-
cance was crossed. The estimator of normal means was
applied after the sequential test as the observations were
judged to be normally distributed.
30
Role of the funding source
No pharmaceutical company was involved in this study.
The funding sources had no input into the study design,
collection, analysis or interpretation of the data, report
preparation or in the decision to submit the paper for pub-
lication. Research grants from the Northern Norway and
Eastern Norway Regional Health Authorities funded the
study.
Results
Between January 2008 and April 2009, 72 women were
enrolled and randomly assigned to treatment (Figure 1).
The stopping boundaries were reached on 13 May 2009
(Figure 2) as a result of a signiﬁcant difference between the
misoprostol and placebo groups on the primary efﬁcacy
outcome. The groups were well balanced in terms of base-
line demographics (Table 1) and surgical characteristics
(Table 2). The results for the cervical dilations are shown
in Table 3. The mean cervical dilatation was 5.7 mm (SD,
1.6 mm) in the misoprostol group and 4.7 mm (SD,
1.5 mm) in the placebo group, the mean difference in cer-
vical dilatation being 1.0 mm (95% CI, 0.2–1.7 mm). The
cervical dilatations were normally distributed, assessed visu-
ally with a bell curve. The main adverse effect was lower
abdominal pain (Table 4), although the majority of women
reported mild pain. One woman who received misoprostol
reported lower abdominal pain rated at a level of six out of
10 on a visual analogue scale score, but reported that her
symptoms subsided after the intake of two 500-mg paracet-
amol tablets. A few of the women who experienced pain
reported that they had taken off-prescription analgesics
(such as paracetamol and ibuprofen) with a subsequent
reduction in their symptoms. No women experienced
severe pain (more than six out of 10 on a visual analogue
scale score). Two women in the misoprostol group (6.1%)
experienced light preoperative bleeding. Of the 67 women,
47 (70%) found self-administered vaginal capsules at home
to be completely acceptable, 14 (21%) fairly acceptable, ﬁve
(7.5%) fairly unacceptable and one (1.5%) completely
unacceptable. The main reason given for unacceptability
was the lack of vaginal applicators to aid insertion. There
were two similar preoperative complications, one in each
treatment group: perforation of the uterine fundus with
the resectoscope after dilatation. Both women were dis-
charged on the same day as surgery and neither experi-
enced further complications or needed further treatment.
No postoperative complications were recorded during the
14-day follow-up period.
Discussion
Our trial shows that 1000 lg of misoprostol self-adminis-
tered vaginally 12 hours before day-care hysteroscopy is safe
and effective for cervical ripening compared with placebo in
postmenopausal women after the use of vaginal estradiol
tablets daily for 14 days. This regimen is highly acceptable
and easy to use. Adverse effects were few and comparatively
minor, the main one being lower abdominal pain (the
maximum experienced being described as ‘moderate’) after
taking the capsules. The Norwegian Medicines Agency
required us to inform all study participants of the risk of
lower abdominal pain as a possible adverse effect, which
may explain why 24% of women in the placebo group
reported lower abdominal pain after taking the capsules.
The main strength of this study was its design to dem-
onstrate whether the vaginal administration of miso-
prostol after pretreatment with estradiol could result in a
signiﬁcant difference in cervical dilatation compared with
Estradiol and misoprostol for cervical ripening
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ble number of study participants. It is an important ethical
issue to reach this conclusion with as few study subjects as
possible exposed to an ineffective drug. The study was
designed and conducted strictly in adherence with the
CONSORT criteria,
31 and the protocol was submitted for
peer review before the trial started to recruit women. Fur-
thermore, the study included all consecutive women
referred to outpatient hysteroscopy. This treatment is also
inexpensive: misoprostol is a stable drug with a long shelf-
life and does not need to be kept refrigerated. Self-adminis-
tration does not require resources from staff — apart from
information — and is not time-consuming. Five 200-lg
tablets of misoprostol (Cytotec , Pﬁzer, Morpeth, UK)
cost less than two euros in Norway, and a packet of 15, 25-
lg estradiol tablets (Vagifem , Novo Nordisk, Ma ˚løv,
Denmark) costs 16 euros. In addition to these costs, the
cost of standard, off-prescription analgesics adds little to
the total therapeutic cost prior to operative hysteroscopy. It
is difﬁcult to calculate a cost–beneﬁt advantage when using
‘complications avoided’ as an endpoint, but there were
fewer complications and fewer difﬁcult dilatations in this
study when compared with the results in a previous inves-
tigation.
23
The main weakness in this study was the validity of eval-
uation of the primary efﬁcacy outcome by each gynaecolo-
gist. The use of preoperative cervical dilatation as a
primary outcome for the assessment of cervical ripening is
open to discussion. However, it is a commonly used out-
come in randomised trials on this topic.
9,22 The use of
other methods, such as a tonometer, to judge the resistance
to cervical dilatation might have provided more objective
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Figure 1. Trial proﬁle.
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with hysteroscopy. Outcomes such as ‘difﬁculty in dilating
the cervix’ and ‘pain experienced by the women’ might
have been open to even greater subjectivity and a much
wider variation in results. A secondary outcome measure of
cervical dilatation of 5 mm was used to reinforce the
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Figure 2. Continuation of the sequential test. The stopping boundaries and the sample path leading to the conclusion that misoprostol was
signiﬁcantly superior to placebo is shown. H0, boundary for the null hypothesis; Ha, boundary for the alternative hypothesis.
Table 2. Indications for operative hysteroscopy and histology result by randomised treatment group
Self-administered
vaginal placebo* (n = 34)
Self-administered vaginal
misoprostol (n = 33)
Indications for hysteroscopy
Asymptomatic endometrial polyp or leiomyoma, n (%) 18 (52.9) 18 (54.5)
Postmenopausal bleeding and endometrial polyp, n (%) 13 (38.2) 11 (33.3)
Lower abdominal pain and endometrial polyp, n (%) 2 (5.9) 2 (6.1)
Vaginal discharge and endometrial polyp, n (%) – 2 (6.1)
Removal of intrauterine device, n (%) 1 (2.9) –
Histology results
Benign histology, n (%) 28 (82.4) 27 (81.8)
Complex endometrial hyperplasia with atypia, n (%) 2 (5.9) 3 (9.1)
Complex endometrial hyperplasia without atypia, n (%) 1 (2.9) 1 (3.0)
Simple endometrial hyperplasia, n (%) 1 (2.9) 1 (3.0)
Endometrial adenocarcinoma, n (%) 1 (2.9) 1 (3.0)
Table 1. Baseline demographic characteristics of women by randomised treatment group
Self-administered
vaginal placebo (n = 34)
Self-administered vaginal
misoprostol (n = 33)
Age (years), mean (SD) 62.4 (6.0) 60.5 (6.8)
Body mass index (kg/m
2), mean (SD) 26.6 (5.1) 28.4 (5.4)
Years of menopause, mean (SD) 12.1 (6.1) 9.9 (6.8)
Total number of children born, mean (SD) 2.0 (1.0) 2.1 (1.2)
Number of vaginal deliveries, mean (SD) 1.9 (1.1) 2.0 (1.2)
Women delivered with caesarean sections, n (%) 2 (5.9) 2 (6.1)
Women with previous cervical dilatation, n (%) 16 (47.1) 14 (42.4)
Women with previous cone biopsy, n (%) 2 (5.9) 2 (6.1)
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ostol. Miniature hysteroscopes do not necessarily require
cervical dilatation, but a 10-mm resectoscope almost always
does. A 1-mm difference in cervical dilatation might be a
questionable outcome if there were only a few women in
the comparison. Used in a trial with a sufﬁcient number of
trial participants, this might be a statistically and clinically
signiﬁcant difference. If no difference between the groups
was found with an outcome measure of 1 mm and a sufﬁ-
ciently high power, one could be reasonably sure that
misoprostol had no effect. In retrospect, we conclude that
we should not have included women who had previously
undergone cervical surgery as eligible for our study. The
postmenopausal women who had previously undergone
cone biopsy in our study had a substantial portion of their
cervix removed, and neither misoprostol nor estradiol had
any ripening effect on the remaining tissue. The study took
longer to complete than expected because of the unexpect-
edly high number of women referred using hormone
replacement therapy independent of the trial, and who
therefore were consequently not eligible for inclusion.
There have been few published studies on the effect of
misoprostol on the postmenopausal cervix, and the results
are inconclusive. Three studies did not ﬁnd a signiﬁcant rip-
ening effect of misoprostol compared with placebo.
15,32,33
Two studies have suggested that misoprostol is effective for
cervical ripening in postmenopausal women,
34,35 but both
studies included postmenopausal women as a subgroup in
their analysis. None of these studies recorded whether the
women were using hormone replacement therapy.
We found only one previous study that investigated the
ripening effect of misoprostol on the estrogen-pretreated
cervix in postmenopausal women.
36 The authors concluded
that misoprostol alone was ineffective for cervical ripening,
but that it was effective in 22 women after they had used
estriol vaginal cream for 14 days prior to dilatation.
Although we could not ﬁnd any literature linking
misoprostol’s cervical ripening effect to the presence or
absence of estrogen, we believe that there is evidence to
suggest a connection. Estrogen appears to be essential for
cervical ripening to take place.
37 Pregnant women with pla-
cental sulphatase deﬁciency (resulting in low circulating
estrogens) do not show ripening of their cervix.
38–42 The
inﬂammatory cascade during the cervical ripening process
involves leucocytes, and the presence of estrogen receptors
on cervical leucocytes
43 suggests that estrogen may directly
regulate leucocyte function in the cervix.
44 The local appli-
cation of estrogen for the induction of labour has been
tried,
45 and estrogen does enhance cervical ripening.
46
However, estrogens appear to be less effective than prosta-
glandins for the induction of labour and delivery, and there
are insufﬁcient data to draw any conclusions.
47 The effect
of estrogen alone on cervical ripening in postmenopausal
women has not been investigated previously. We noticed
that there was a remarkable difference in cervical dilatation
Table 3. Intra-operative ﬁndings, distribution of cervical dilatation and complications by randomised treatment group
Dosage group P
Self-administered vaginal
placebo (n = 34)
Self-administered
vaginal misoprostol (n = 33)
Cervical dilatation at hysteroscopy (mm), mean (SD) 4.7 (1.5) 5.7 (1.6) 0.01
Baseline cervical dilatation (mm) at inclusion, mean (SD) 2.1 (1.7) 2.6 (1.7)
Mean difference in cervical dilatation (mm) between inclusion
and hysteroscopy (SD)
2.7 (1.7) 3.1 (1.9)
Number of patients achieving cervical dilatation ‡5 mm, n (%) 20 (59) 30 (88)
‘Difﬁcult dilatation’, n (%) 7 (21) 1 (3)
Exposure to capsules (min), mean (SD) 726 (109) 750 (84)
Frequency of preoperative complications, n (%) 1 (3) 1 (3)
Complications within 14 days after hysteroscopy, n (%) 0 0
Table 4. Preoperative adverse effects by randomised treatment
group
Self-administered
vaginal placebo
(n = 34)
Self-administered
vaginal misoprostol
(n = 33)
No adverse effects, n (%) 23 (67.6) 18 (54.5)
Lower abdominal pain, n (%) 8 (23.5) 13 (39.4)
Mean level of reported
preoperative pain* (SD)
1.0 (1.7) 1.5 (2.1)
Constipation, n (%) 2 (5.9) 0
Vaginal bleeding, n (%) 0 2 (6.1)
Vaginal discharge, n (%) 1 (2.9) 0
*Measured with a visual analogue scale score, ranging from 0 (no
pain) to 10 (unbearable pain).
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outpatient’s consultation and that taken just before hyster-
oscopy. The postmenopausal women in the placebo group
were also noticeably easier to dilate compared with the
postmenopausal women receiving placebo in our previous
study (who had not used hormone therapy). This suggests
the possibility that estradiol alone has a substantial effect
on the remodelling and ripening of cervical tissue in only
14 days. Further studies are needed to conﬁrm this, as our
trial was only designed to measure the difference in cervical
dilatation between the misoprostol and placebo groups.
Future trials investigating the ripening effect of misoprostol
on the postmenopausal cervix must also include informa-
tion on whether women are using hormone therapy. We
suspect that the varying effect of misoprostol on cervical
ripening may have been caused by different levels of circu-
lating estrogens. Women who are in early pregnancy
require much higher doses of misoprostol for cervical rip-
ening, compared with women at term.
14 Twenty-ﬁve
micrograms of misoprostol are sufﬁcient to initiate cervical
ripening and to induce labour in pregnant women at term,
whereas doses of 800 lg are recommended for the induc-
tion of ﬁrst-trimester abortion. We also found misoprostol
to be much less effective in non-pregnant women than in
pregnant women in our previous studies.
23,48,49
Misoprostol is a safe and well-tolerated drug. The dos-
ages chosen for previous trials on non-pregnant women
have been similar to those used prior to the termination of
pregnancy (the majority using 400 lg of misoprostol).
Misoprostol generally has a far weaker and more unpre-
dictable cervical ripening effect in non-pregnant (pre- and
postmenopausal) than pregnant women. This could explain
why other previous trials have concluded that misoprostol
is ineffective for cervical ripening with lower doses and
other administration methods, compared with placebo. The
only previous trial we found that described the use of
1000 lg of vaginal misoprostol for cervical ripening con-
cluded that it was not effective if given 2–4 hours before
surgery.
50 We chose a higher dosage of vaginally adminis-
tered misoprostol, and a longer administration to operation
interval, because there was no clear consensus from previ-
ous trials as to whether misoprostol has a signiﬁcant ripen-
ing effect in non-pregnant women. Such a large dose given
orally would probably result in signiﬁcant gastrointestinal
and possibly other systemic adverse effects. The failure of
misoprostol in previous trials to have any effect on cervical
ripening may have been the result of an inadequate dosage
or insufﬁcient time between the delivery of the tablets and
operation.
Long-term estradiol therapy is contraindicated in women
who have previously had, or have current or suspected,
breast cancer, current or suspected estrogen-dependent
tumours, untreated endometrial hyperplasia, undiagnosed
genital bleeding, deep-vein thrombosis or porphyria. As far
as we are aware, there is no evidence to suggest that 14 days
of local 25-lg estradiol treatment would pose a safety risk
to women, although every woman must be assessed before
treatment is prescribed on an individual basis.
Conclusions
One thousand micrograms of self-administered vaginal
misoprostol, administered 12 hours prior to operative
hysteroscopy, has a signiﬁcant cervical ripening effect
compared with placebo in postmenopausal women after
14 days of pretreatment with vaginal estradiol. Estrogen
therapy appears to be necessary for cervical ripening to
occur with misoprostol in postmenopausal women. Self-
administered vaginal administration of 1000 lg of misopr-
ostol at home on the evening before operative hysteros-
copy is safe and highly acceptable, although there is a risk
of lower abdominal pain and light preoperative bleeding
with this regimen, and women should be made aware of
this and offered standard analgesics. Based on the results
of our study, we believe the practical dose and timing in
postmenopausal women to be 1000 lg of misoprostol self-
administered vaginally at home about 12 hours before
operative hysteroscopy, after 14 days of pretreatment with
vaginal estradiol. We would recommend offering this inex-
pensive and easy to use regimen to postmenopausal
women prior to undergoing operative hysteroscopy to
reduce the risk of complications and to facilitate cervical
dilatation.
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